BMS Inks Potential $8.4B Deal for SystImmune’s ADC for Lung, Breast Cancer

Redmond-based biotech company Systimmune has secured an exclusive license and collaboration agreement with Bristol Myers Squibb (BMS) to support the development of its solid tumor treatment. The total potential value of the deal is $8.4 billion.

The treatment, bi-specific antibody-drug conjugate BL-B01D1 targets two protein classes that have a high prevalence in solid tumors. It works by disrupting cancer cell processes, preventing the cells from multiplying and surviving in the body.

BL-B01D1 is now undergoing global Phase I testing after exhibiting promise in previous clinical research. Samit Hirawat, BMS’ chief medical officer, said the deal will help, “strengthen our approach of matching the most appropriate therapeutic modality to areas of unmet medical need across solid tumor oncology.”

READ THE STORY at BioSpace »